Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: BIBW 2992

First Posted Date: 2007-09-05

Last Posted Date: 2016-09-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 129

Registration Number: NCT00525148

Locations: 🇨🇳
1200.22.88602 Veterans General Hospital, Taipei, Taiwan
🇨🇳
1200.22.88601 National Taiwan University Hospital, Taipei, Taiwan
🇺🇸
1200.22.28 Boehringer Ingelheim Investigational Site, Bakersfield, California, United States

and more 27 locations

Trial Comparing Tiotropium Inhalation Capsules vs Placebo in Chronic Obstructive Pulmonary Disease (COPD).

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: tiotropium

First Posted Date: 2007-09-03

Last Posted Date: 2014-05-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 457

Registration Number: NCT00523991

Locations: 🇵🇹
205.365.1025 Boehringer Ingelheim Investigational Site, Amadora, Portugal
🇨🇿
205.365.1107 Boehringer Ingelheim Investigational Site, Hradec Kralove, Czech Republic
🇨🇿
205.365.1079 Boehringer Ingelheim Investigational Site, Neratovice, Czech Republic

and more 59 locations

Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

Phase 3

Terminated

Conditions: HIV Infections

First Posted Date: 2007-08-16

Last Posted Date: 2014-05-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT00517192

Locations: 🇨🇦
1182.71.1002 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇧🇸
1182.71.1016 Boehringer Ingelheim Investigational Site, Nassau, Bahamas
🇵🇹
1182.71.3502 Boehringer Ingelheim Investigational Site, Amadora, Portugal

and more 51 locations

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

Phase 2

Completed

Conditions: Pulmonary Fibrosis

Interventions: Drug: placebo
Drug: low dose BIBF 1120 twice daily
Drug: intermediate dose BIBF 1120 twice daily
Drug: high dose BIBF 1120 twice daily
Drug: low dose BIBF1120 once daily

First Posted Date: 2007-08-10

Last Posted Date: 2015-01-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 432

Registration Number: NCT00514683

Locations: 🇦🇷
1199.30.54002 Boehringer Ingelheim Investigational Site, Mendoza, Argentina
🇧🇪
1199.30.32001 Boehringer Ingelheim Investigational Site, Leuven, Belgium
🇧🇪
1199.30.32002 Boehringer Ingelheim Investigational Site, Yvoir, Belgium

and more 89 locations

BIBW 2992 (Afatinib) in Head & Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Neoplasms
Carcinoma, Squamous Cell

Interventions: Drug: BIBW 2992
Drug: Cetuximab

First Posted Date: 2007-08-10

Last Posted Date: 2016-07-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 124

Registration Number: NCT00514943

Locations: 🇺🇸
1200.28.0024 Boehringer Ingelheim Investigational Site, Baltimore, Maryland, United States
🇺🇸
1200.28.0001 Boehringer Ingelheim Investigational Site, Chicago, Illinois, United States
🇺🇸
1200.28.0010 Boehringer Ingelheim Investigational Site, Stanford, California, United States

and more 33 locations

Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients

Phase 3

Completed

Conditions: Early Parkinson Disease (Early PD)

Interventions: Drug: Pramipexol Immediate Release
Drug: Pramipexol Extended Release
Drug: Placebo

First Posted Date: 2007-05-28

Last Posted Date: 2014-07-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 539

Registration Number: NCT00479401

Locations: 🇭🇺
248.524.36008 Boehringer Ingelheim Investigational Site, Miskolc, Hungary
🇮🇳
248.524.91010 Boehringer Ingelheim Investigational Site, Hyderabad, India
🇮🇳
248.524.91001 Boehringer Ingelheim Investigational Site, Karnataka, India

and more 92 locations

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

Phase 4

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Placebo
Drug: Pramipexole

First Posted Date: 2007-05-11

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 331

Registration Number: NCT00472199

Locations: 🇬🇧
248.629.44003 Boehringer Ingelheim Investigational Site, Chorley, United Kingdom
🇪🇸
248.629.3402 Boehringer Ingelheim Investigational Site, Barcelona, Spain
🇬🇧
248.629.44004 Boehringer Ingelheim Investigational Site, Glasgow, United Kingdom

and more 39 locations

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Phase 2

Completed

Conditions: Asthma

First Posted Date: 2007-05-01

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 296

Registration Number: NCT00467740

Locations: 🇨🇦
1222.6.004 Boehringer Ingelheim Investigational Site, Saskatoon, Saskatchewan, Canada
🇨🇦
1222.6.006 Boehringer Ingelheim Investigational Site, Vancouver, British Columbia, Canada
🇺🇸
1222.6.073 Boehringer Ingelheim Investigational Site, Wheat Ridge, Colorado, United States

and more 34 locations

Pivotal Study in Advanced Parkinsons Disease Patients

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: Pramipexol Extended Release
Drug: Pramipexol Immediate Release
Drug: Placebo

First Posted Date: 2007-04-27

Last Posted Date: 2014-07-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 517

Registration Number: NCT00466167

Locations: 🇦🇹
248.525.43005 Boehringer Ingelheim Investigational Site, Linz, Austria
🇰🇷
248.525.82008 Boehringer Ingelheim Investigational Site, Kyeonggi-do, Korea, Republic of
🇮🇹
248.525.39005 Università La Sapienza di Roma, Roma, Italy

and more 73 locations

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Patients With COPD.

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive
Asthma

First Posted Date: 2007-03-27

Last Posted Date: 2014-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 409

Registration Number: NCT00452400

Locations: 🇺🇸
1222.5.02 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States
🇨🇦
1222.5.040 Respiratory Research Lab, Toronto, Ontario, Canada
🇨🇦
1222.5.034 Pulmonary Care Clinic and Research Centre, Toronto, Ontario, Canada

and more 39 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy